Portola Pharmaceuticals (PTLA) Issues Quarterly Earnings Results

Portola Pharmaceuticals (NASDAQ:PTLA) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.54) by $0.46, Briefing.com reports. Portola Pharmaceuticals had a negative return on equity of 111.64% and a negative net margin of 1,503.29%. The company had revenue of $14.20 million for the quarter, compared to the consensus estimate of $7.10 million. During the same quarter last year, the company posted ($1.41) earnings per share. The company’s revenue for the quarter was up 270.8% compared to the same quarter last year.

Shares of PTLA traded down $0.97 during mid-day trading on Friday, hitting $22.17. The company’s stock had a trading volume of 50,447 shares, compared to its average volume of 1,482,546. Portola Pharmaceuticals has a one year low of $18.18 and a one year high of $56.70. The company has a current ratio of 6.69, a quick ratio of 6.59 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -4.59 and a beta of 2.04.

Several equities analysts have commented on PTLA shares. Zacks Investment Research upgraded Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Thursday, October 11th. ValuEngine downgraded Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 13th. Oppenheimer set a $60.00 price target on Portola Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 10th. BidaskClub downgraded Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 22nd. Finally, William Blair reiterated a “buy” rating on shares of Portola Pharmaceuticals in a report on Monday, August 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $43.43.

In other Portola Pharmaceuticals news, Director Jeffrey W. Bird acquired 137,563 shares of Portola Pharmaceuticals stock in a transaction dated Tuesday, August 21st. The stock was bought at an average cost of $25.17 per share, with a total value of $3,462,460.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey W. Bird acquired 390,000 shares of Portola Pharmaceuticals stock in a transaction dated Thursday, August 23rd. The stock was acquired at an average cost of $25.84 per share, with a total value of $10,077,600.00. The disclosure for this purchase can be found here. 4.60% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. SeaCrest Wealth Management LLC bought a new position in Portola Pharmaceuticals in the second quarter worth $191,000. BB&T Securities LLC bought a new position in Portola Pharmaceuticals in the second quarter worth $201,000. Smith Asset Management Group LP lifted its position in Portola Pharmaceuticals by 51.1% in the third quarter. Smith Asset Management Group LP now owns 8,100 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 2,740 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Portola Pharmaceuticals in the second quarter worth $230,000. Finally, Quantitative Systematic Strategies LLC bought a new position in Portola Pharmaceuticals in the second quarter worth $234,000. 94.47% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by WKRB News and is the property of of WKRB News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.wkrb13.com/2018/11/09/portola-pharmaceuticals-ptla-issues-quarterly-earnings-results.html.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.

See Also: Rule of 72

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply